← Back to Awards
NIHNATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
Development of an Optimized Adjuvanted TB Vaccine
- Institution
- University of Montana, MT
- Principal investigator
- Jay Evans
- Funding
- $359K
- Duration
- 2021–2025
32/100
Abstract
To identify the optimal adjuvant for recombinant vaccines and inactivated flu vaccines, and to identify correlates of protection against infection or disease, experimental vaccines will be formulated with a panel of different vaccine adjuvants and tested side-by-side for immunogenicity and efficacy.
LOADING MOONBASE SCORE
Questions for University of Montana
Answered by the team behind this research.
No questions yet. Sign in to ask the first one
Related grants
Same researchers, same institution, scored first.
- NIH · University of Montana55
DEVELOPMENT OF UM-1098: A NOVEL SYNTHETIC TH17 INDUCING ADJUVANT AND DELIVERY SYSTEM
Jay Evans · $1.6M · 2023–2026
- NIH · University of Montana48
Identification of Novel Syk/Raf-1 Mediated CLR Ligands as Vaccine Adjuvants
Jay Evans · $1.6M · 2025–2026
- NIH · University of Montana42
DEVELOPMENT OF UM-1098: A NOVEL SYNTHETIC TH17 INDUCING ADJUVANT AND DELIVERY SYSTEM
Jay Evans · $5.5M · 2023–2028